Wilson's Disease: Diagnostic Work-Up and Treatment in Patients Under 30
In a patient under 30 presenting with unexplained acute liver injury, you must immediately pursue a comprehensive diagnostic evaluation for Wilson's disease including slit-lamp examination for Kayser-Fleischer rings, serum ceruloplasmin, 24-hour urinary copper excretion, and hepatic copper content if diagnosis remains uncertain, followed by lifelong copper chelation therapy once confirmed. 1
When to Suspect Wilson's Disease
Wilson's disease must be on your differential for:
- Any unexplained liver disease (acute hepatitis, chronic hepatitis, cirrhosis, or acute liver failure) in patients under 30
- Unexplained liver disease combined with neuropsychiatric symptoms
- Acute hepatitis accompanied by hemolytic anemia and rapid jaundice onset
- Any neurological movement disorder of uncertain cause, regardless of age 1
Critical pitfall: Age alone should never exclude Wilson's disease—while most present between ages 5-35, cases have been diagnosed from age 3 to the eighth decade 1. However, the under-30 age group represents the highest-risk population requiring aggressive evaluation.
Diagnostic Algorithm
Step 1: Initial Clinical Assessment
Look specifically for:
Kayser-Fleischer rings: Require slit-lamp examination by a skilled ophthalmologist. These are golden-brown rings in Descemet's membrane of the cornea 1
Neuropsychiatric features: Movement disorders, behavioral changes, psychiatric symptoms
Family history: Liver disease or neurological disorders in siblings
Step 2: Laboratory Evaluation
Order the following tests simultaneously:
Serum ceruloplasmin (most accessible screening test):
- Typically <0.1 g/L in Wilson's disease 1
- Critical limitation: Normal levels do NOT exclude Wilson's disease
24-hour urinary copper excretion:
- >1.6 μmol/24h is typical in symptomatic patients 1
- In children with mild hepatic disease, may be only mildly elevated or even normal
- Lower threshold of >0.64 μmol/24h useful for asymptomatic patients but less specific 1
- Most sensitive test in hepatic presentations 5
Hepatic parenchymal copper content (when diagnosis uncertain):
- >4 μmol/g dry weight provides critical diagnostic confirmation 1
- Normal hepatic copper (<0.64-0.8 μmol/g) almost always excludes Wilson's disease in untreated patients 1
- Should be obtained in younger patients and non-straightforward cases 1
Step 3: Apply the Leipzig Scoring System
Use this validated diagnostic score when initial tests are equivocal 1:
- Score ≥4: Diagnosis highly likely, proceed to treatment
- Score 2-3: Diagnosis possible, pursue genetic testing
- Score 0-1: Diagnosis unlikely, consider alternatives
The scoring system proved valuable even in atypical presentations without classic features 3.
Step 4: Neuroimaging and Genetic Testing
Brain MRI:
- Should be performed in ALL patients with neurologic symptoms before treatment 1
- Consider in hepatic presentations to detect subclinical involvement
Genetic testing (ATP7B gene):
- Whole-gene sequencing or specific mutation analysis
- Primary screening method for first-degree relatives of confirmed patients 1
- Confirms diagnosis when clinical picture uncertain
- Over 500 mutations described; 380 confirmed pathogenic 1
Treatment Approach
Immediate Management
Once diagnosis is confirmed, treatment must be lifelong 1. There are no high-quality randomized trials comparing treatments, so recommendations are based on extensive case series 1.
First-Line Chelation Therapy: D-Penicillamine
D-Penicillamine dosing:
- Adults: 750-1500 mg/day in 2-3 divided doses 1
- Children: 20 mg/kg/day rounded to nearest 250 mg, in 2-3 divided doses 1
- Administer 1 hour before meals (food inhibits absorption) 1
- Always supplement with pyridoxine 25-50 mg/day (D-penicillamine interferes with pyridoxine) 1
Monitoring treatment adequacy:
- 24-hour urinary copper excretion highest immediately after starting (may exceed 16 μmol/1000 μg per 24h)
- Long-term monitoring guides dose adjustments 1
Alternative Chelators
- Trientine: Alternative when D-penicillamine not tolerated
- Zinc salts: Maintenance therapy option
- Tetrathiomolybdate: Investigational 1
Special Situation: Acute Liver Failure
Medical therapy rarely effective in fulminant hepatic failure due to Wilson's disease 1.
Prognostic scoring (modified King's College criteria):
- Score >11 is always fatal without liver transplantation 1
- Urgent transplant evaluation required
Liver transplantation provides definitive cure by replacing the defective ATP7B gene and should be considered early in acute liver failure presentations 1.
Critical Pitfalls to Avoid
Never exclude Wilson's disease based on normal ceruloplasmin alone—up to 36% of pediatric cases have normal levels 1
Absence of Kayser-Fleischer rings does NOT exclude diagnosis—commonly absent in purely hepatic presentations 1
Don't wait for all test results in acute liver failure—calculate prognostic score and refer for transplant evaluation immediately if score >11 1
Never stop treatment once started—Wilson's disease requires lifelong therapy; discontinuation leads to fatal copper reaccumulation 1
Screen all first-degree relatives using genetic testing—this is the only reliable method to identify affected siblings 1
Consider Wilson's even with positive autoantibodies—the disease can mimic autoimmune hepatitis with hypergammaglobulinemia and positive autoantibodies 6